H.C. Wainwright lowered the firm’s price target on Crescent Biopharma (CBIO) to $22 from $25 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO:
- Crescent Biopharma reports Q4 EPS ($4.01) vs. ($19.74) last year
- Crescent Biopharma sees cash runway into 2028
- 3 ‘Strong Buy’ Stocks to Buy Now, 2/19/2026, According to Top Analysts
- Crescent Biopharma announces grants of inducement awards
- Crescent Biopharma: Fast-Follower Potential of CR-001 and Strategic Partnerships Support Buy Rating and $25 Target